“As small molecule science makes incredible advances, the cost of drug discovery is higher than ever, weighed down by complex workflows and fragmented data and analytics solutions,” said Mike McKee, president of Dotmatics. “We want to significantly improve this process by developing an integrated platform with a wide range of tools, including GraphPad Prism, SnapGene and our flow cytometry solutions from Dotmatics, which are trusted by the world’s leading scientific organizations.

The small molecule drug discovery solution promotes increased collaboration and productivity between research teams, reduces operational inefficiencies, and accelerates the process of transferring data from insights to decisions. These benefits are accelerating progress toward life-enhancing drug therapies. In May, Dotmatics presented its Biology Solution for Antibody Discoverywhich combines Dotmatics Enterprise Science Platform with advanced application software commonly used in antibody discovery labs. Together, these solutions constitute the most comprehensive set of chemical and biological offerings on the market.

In United States alone, the Congressional Budget Office reported in 2021 that annual spending on pharmaceutical research and development was $83 billions of dollars – more than 10 times the annual spending of the 1980s, even adjusted for inflation. Meanwhile, productivity in research labs has declined as workflows have become more complex and data sets much larger and more fragmented.

Data for small molecule drug discovery is typically siled in proprietary systems, forcing scientists to choose between compromising speed or accuracy. Lack of extractable and composable data and disconnected workflows force researchers to manually process data, which introduces risks of data errors, inefficiencies, and review burden.

The new Dotmatics Small Molecule Drug Discovery solution helps researchers solve these problems, providing targeted capabilities and models that provide a unified workspace that supports the entire workflow from hit discovery to Lead optimization research, including design, synthesis, sample logistics, QC analysis, screening, and SAR analysis. Meanwhile, guided visualizations and preconfigured chemoinformatics analysis capabilities empower medical chemists to make better-informed decisions, faster.

Small molecule solution in action

As a CRO with more than 100 facilities in more than 20 countries, Charles River Laboratories knows that streamlining processes and integrating applications can have a dramatic impact on their drug discovery and development efforts. In recent years, the company has focused on developing the “laboratory of the future”. They have strategically migrated to cloud-based and SaaS offerings, including Dotmatics solutions in its Discovery business unit for database search, compound registration and workflow creation. More recently, the Early Discovery business unit deployed the ELN Dotmatics for Biology, Chemistry and DMPK to approximately 500 researchers in the UK and the Netherlands.

“Dotmatics solutions not only help optimize our internal processes, but they also help us better serve our customers, which we know ultimately benefits patients,” said Riannon Hambleton, Director Business Technology Partnership for Discovery for Charles River Laboratories. “We really look forward to working with Dotmatics again to help us move forward into the lab of the future.”

And since Dotmatics can support an end-to-end workflow, customers can optimize their IT ecosystem by replacing outdated applications and closing capacity gaps. This not only reduces technical debt, but also reduces the total cost of ownership associated with working with multiple vendors and the licenses, services, and training that come with it.

Lab managers can now rely on a secure, cloud-based data management platform that simplifies lab data governance, along with proven science apps and productivity tools their researchers trust. The solution automates manual and error-prone data analysis tasks and centralizes data management, helping organizations make smarter decisions and ultimately accelerating the discovery of critical drugs and therapies.

The Dotmatics Small Molecule Drug Discovery solution integrates FAIR data practices and provides a single, broad and deep solution from discovering successes to optimizing leads to advance to animal testing and translational medicine.

About Dotmatics
Dotmatics is a leader in scientific R&D software connecting science, data and decision making. Its enterprise R&D platform and science-preferred applications drive efficiency and accelerate innovation. Over 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner and safer world. Dotmatics is a global team of over 800 people dedicated to supporting customers in over 180 countries. The head office of the company is located at Bostonwith 14 offices and R&D teams spread across the world.

Dotmatics is based on Insight Partners, a leading global venture capital and private equity firm that invests in high-growth technology and software companies. Learn more about Dotmatics, its platform and applications including GraphPad Prism, Geneious, SnapGene, Protein Metrics and LabArchives at https://www.dotmatics.com.

SOURCE Dotmatics Inc.